BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 27699218)

  • 1. The MEK inhibitor trametinib separates murine graft-versus-host disease from graft-versus-tumor effects.
    Itamura H; Shindo T; Tawara I; Kubota Y; Kariya R; Okada S; Komanduri KV; Kimura S
    JCI Insight; 2016 Jul; 1(10):e86331. PubMed ID: 27699218
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological MEK inhibition promotes polyclonal T-cell reconstitution and suppresses xenogeneic GVHD.
    Itamura H; Shindo T; Muranushi H; Kitaura K; Okada S; Shin-I T; Suzuki R; Takaori-Kondo A; Kimura S
    Cell Immunol; 2021 Sep; 367():104410. PubMed ID: 34274730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorylated ERK1/2 in CD4 T cells is associated with acute GVHD in allogeneic hematopoietic stem cell transplantation.
    Itamura H; Shindo T; Yoshioka S; Ishikawa T; Kimura S
    Blood Adv; 2020 Feb; 4(4):667-671. PubMed ID: 32078679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MEK inhibitors selectively suppress alloreactivity and graft-versus-host disease in a memory stage-dependent manner.
    Shindo T; Kim TK; Benjamin CL; Wieder ED; Levy RB; Komanduri KV
    Blood; 2013 Jun; 121(23):4617-26. PubMed ID: 23575444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MEK inhibitor trametinib does not prevent the growth of anaplastic lymphoma kinase (ALK)-addicted neuroblastomas.
    Umapathy G; Guan J; Gustafsson DE; Javanmardi N; Cervantes-Madrid D; Djos A; Martinsson T; Palmer RH; Hallberg B
    Sci Signal; 2017 Nov; 10(507):. PubMed ID: 29184034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential requirement for a cellular type-1 immune response in tumor-associated versus alloantigen-targeted GvT effects.
    Stelljes M; Specht C; Albring J; Volkmann S; Schlösser V; Pauels HG; Poremba C; Bisping G; Opitz C; Scheffold C; Silling G; Kiehl M; Berdel WE; Kienast J
    Transplantation; 2007 Feb; 83(3):314-22. PubMed ID: 17297406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intestinal helminths regulate lethal acute graft-versus-host disease and preserve the graft-versus-tumor effect in mice.
    Li Y; Chen HL; Bannick N; Henry M; Holm AN; Metwali A; Urban JF; Rothman PB; Weiner GJ; Blazar BR; Elliott DE; Ince MN
    J Immunol; 2015 Feb; 194(3):1011-20. PubMed ID: 25527786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trametinib Attenuates Delayed Rejection and Preserves Thymic Function in Rat Lung Transplantation.
    Takahagi A; Shindo T; Chen-Yoshikawa TF; Yoshizawa A; Gochi F; Miyamoto E; Saito M; Tanaka S; Motoyama H; Aoyama A; Takaori-Kondo A; Date H
    Am J Respir Cell Mol Biol; 2019 Sep; 61(3):355-366. PubMed ID: 30849233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Marked in Vivo Donor Regulatory T Cell Expansion via Interleukin-2 and TL1A-Ig Stimulation Ameliorates Graft-versus-Host Disease but Preserves Graft-versus-Leukemia in Recipients after Hematopoietic Stem Cell Transplantation.
    Wolf D; Barreras H; Bader CS; Copsel S; Lightbourn CO; Pfeiffer BJ; Altman NH; Podack ER; Komanduri KV; Levy RB
    Biol Blood Marrow Transplant; 2017 May; 23(5):757-766. PubMed ID: 28219835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant IL-7/HGFβ hybrid cytokine separates acute graft-versus-host-disease from graft-versus-tumour activity by altering donor T cell trafficking.
    Hu R; Liu Y; Song Y; Su M; Lu X; Rood D; Lai L
    Br J Haematol; 2016 Nov; 175(3):505-516. PubMed ID: 27447780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Extracellular adenosine is a therapeutic target for limiting graft-versus-host disease and enhancing the graft-versus-tumor effect against hematopoietic malignancy].
    Tsukamoto H
    Yakugaku Zasshi; 2014; 134(10):1021-7. PubMed ID: 25274211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trametinib (GSK1120212).
    Zeiser R; Andrlová H; Meiss F
    Recent Results Cancer Res; 2018; 211():91-100. PubMed ID: 30069762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multidonor bone marrow transplantation improves donor engraftment and increases the graft versus tumor effect while decreasing graft-versus-host disease.
    Zhanna Y; Ester H; Lola W; Offer G; Shimon S; Shapira MY
    Transpl Int; 2011 Feb; 24(2):194-200. PubMed ID: 20854413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GSK3 inhibition prevents lethal GVHD in mice.
    Klamer G; Shen S; Song E; Rice AM; Knight R; Lindeman R; O'Brien TA; Dolnikov A
    Exp Hematol; 2013 Jan; 41(1):39-55.e10. PubMed ID: 22999867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression.
    Schräder T; Dudek SE; Schreiber A; Ehrhardt C; Planz O; Ludwig S
    Antiviral Res; 2018 Sep; 157():80-92. PubMed ID: 29990517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.
    Cavalloni G; Peraldo-Neia C; Varamo C; Chiorino G; Sassi F; Aglietta M; Leone F
    Oncotarget; 2016 Aug; 7(32):52354-52363. PubMed ID: 27429047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trametinib, a novel MEK kinase inhibitor, suppresses lipopolysaccharide-induced tumor necrosis factor (TNF)-α production and endotoxin shock.
    Shi-Lin D; Yuan X; Zhan S; Luo-Jia T; Chao-Yang T
    Biochem Biophys Res Commun; 2015 Mar; 458(3):667-673. PubMed ID: 25684183
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.